Literature DB >> 12871312

Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist.

N Lenain1, M Freund, C Léon, J-P Cazenave, C Gachet.   

Abstract

Previous studies in experimental models revealed a role for the P2Y1 platelet ADP receptor in systemic vascular thromboembolism models. In the present work, we used models of localized arterial and venous thrombosis to assess the role of the P2Y1 receptor in these processes. Arterial thrombosis was induced in one mesenteric arteriole of a mouse using FeCl3, while venous thrombosis was studied in a Wessler model adapted to rats. P2Y1-deficient mice and mice treated with the P2Y1 antagonist MRS2179 displayed significantly less arterial thrombosis than their respective controls. Combination of P2Y1 deficiency with P2Y12 inhibition led to a significant additive effect. Venous thrombosis was slightly but significantly inhibited in MRS2179-treated rats. These results demonstrate a role for the P2Y1 receptor in both arterial and venous thrombosis, further establishing this receptor as a potential target for antithrombotic drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871312     DOI: 10.1046/j.1538-7836.2003.00144.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  21 in total

Review 1.  Central role of the P2Y12 receptor in platelet activation.

Authors:  Robert T Dorsam; Satya P Kunapuli
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

2.  Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.

Authors:  B Labarthe; J Babin; M Bryckaert; P Théroux; A Bonnefoy
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 3.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

4.  The P2Y1 receptor-mediated leukocyte adhesion to endothelial cells is inhibited by melatonin.

Authors:  Tassya Cataldi Cardoso; Thaís Emanuelle Pompeu; Claudia Lucia Martins Silva
Journal:  Purinergic Signal       Date:  2017-05-29       Impact factor: 3.765

5.  P2 receptors and platelet function.

Authors:  Béatrice Hechler; Christian Gachet
Journal:  Purinergic Signal       Date:  2011-07-27       Impact factor: 3.765

6.  Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.

Authors:  Zubair A Karim; Hari Priya Vemana; Fatima Z Alshbool; Olivia A Lin; Abdullah M Alshehri; Payam Javaherizadeh; Enma V Paez Espinosa; Fadi T Khasawneh
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-01-15       Impact factor: 8.311

7.  Thrombosis: Novel nanomedical concepts of diagnosis and treatment.

Authors:  Iwona Cicha
Journal:  World J Cardiol       Date:  2015-08-26

8.  Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor.

Authors:  Marco Cattaneo; Anna Lecchi; Michihiro Ohno; Bhalchandra V Joshi; Pedro Besada; Susanna Tchilibon; Rossana Lombardi; Norbert Bischofberger; T Kendall Harden; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2004-11-15       Impact factor: 5.858

9.  Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation.

Authors:  Sven Nylander; Christer Mattsson; Sofia Ramström; Tomas L Lindahl
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

10.  Endobrevin/VAMP-8-dependent dense granule release mediates thrombus formation in vivo.

Authors:  Gwenda J Graham; Qiansheng Ren; James R Dilks; Price Blair; Sidney W Whiteheart; Robert Flaumenhaft
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.